Selective inhibition of alpha/beta-hydrolase domain 6 attenuates neurodegeneration, alleviates blood brain barrier breakdown, and improves functional recovery in a mouse model of traumatic brain injury

Journal of Neurotrauma

Volumn 30, Issue 7, 2013, Pages 565-579

  Tchantchou, Flaubert ^a   Zhang, Yumin ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

2 arachidonylglycerol; ABHD6; neuroinflammation; neuroprotection; traumatic brain injury

Indexed keywords

ARGINASE 1; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CYCLOOXYGENASE 2; INDUCIBLE NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE; NEUROPROTECTIVE AGENT; PROTEIN KINASE B; UNCLASSIFIED DRUG; WWL 70;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CORTEX; BRAIN DAMAGE; BRAIN SIZE; CONTROLLED STUDY; CONVALESCENCE; DENTATE GYRUS; MACROPHAGE; MALE; MICROGLIA; MOTOR COORDINATION; MOUSE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRAUMATIC BRAIN INJURY; UPREGULATION; WORKING MEMORY;

ANIMALS; ARACHIDONIC ACIDS; BIPHENYL COMPOUNDS; BLOOD-BRAIN BARRIER; BLOTTING, WESTERN; BRAIN INJURIES; CARBAMATES; DISEASE MODELS, ANIMAL; ENDOCANNABINOIDS; ENZYME INHIBITORS; GLYCERIDES; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; MONOACYLGLYCEROL LIPASES; NERVE DEGENERATION; RECOVERY OF FUNCTION;

EID: 84875409960     PISSN: 08977151     EISSN: 15579042     Source Type: Journal    
DOI: 10.1089/neu.2012.2647     Document Type: Article

References (84)

1. Loane, D.J., Pocivavsek, A., Moussa, C.E., Thompson, R., Matsuoka, Y., Faden, A.I., Rebeck, G.W., and Burns, M.P. (2009). Amyloid precursor protein secretases as therapeutic targets for traumatic brain injury. Nat. Med. 15, 377-379.
2. Pitkänen, A., Longhi, L., Marklund, N., Morales, D.M., and McIntosh, T.K. (2005). Neurodegeneration and neuroprotective strategies after traumatic brain injury. Drug Discov. Today: Disease Mechanisms 2, 409-418.
3. Faul, M., Xu, L., Wald, M., and Coronado, V. (2010). Traumatic Brain Injury in the United States: Emergency Department Visits, Hospitalizations and Deaths 2002-2006. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control: Atlanta, GA.
4. Jain, K.K. (2008). Neuroprotection in traumatic brain injury. Drug Discov. Today 13, 1082-1089.
5. Loane, D.J., and Faden, A.I. (2010). Neuroprotection for traumatic brain injury: translational challenges and emerging therapeutic strategies. Trends Pharmacol. Sci. 31, 596-604.
6. Werner, C., and Engelhard, K. (2007). Pathophysiology of traumatic brain injury. Br. J. Anaesth. 99, 4-9.
7. Di Marzo, V., Bifulco, M., and De Petrocellis, L. (2004). The endocannabinoid system and its therapeutic exploitation. Nat. Rev. Drug Discov. 3, 771-784.
8. Mackie, K. (2006). Cannabinoid receptors as therapeutic targets. Annu. Rev. Pharmacol. Toxicol. 46, 101-122.
9. Shohami, E., Cohen-Yeshurun, A., Magid, L., Algali, M., and Mechoulam, R. (2011). Endocannabinoids and traumatic brain injury. Br. J. Pharmacol. 163, 1402-1410.
10. Cohen-Yeshurun, A., Trembovler, V., Alexandrovich, A., Ryberg, E., Greasley, P.J., Mechoulam, R., Shohami, E., and Leker, R.R. (2011). N-arachidonoyl-L-serine is neuroprotective after traumatic brain injury by reducing apoptosis. J. Cereb. Blood Flow Metab. 31, 1768-1777.
11. Panikashvili, D., Shein, N.A., Mechoulam, R., Trembovler, V., Kohen, R., Alexandrovich, A., and Shohami, E. (2006). The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol. Dis. 22, 257-264.
12. Panikashvili, D., Simeonidou, C., Ben-Shabat, S., Hanus, L., Breuer, A., Mechoulam, R., and Shohami, E. (2001). An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413, 527-531.
13. van der Stelt, M., Veldhuis, W.B., van Haaften, G.W., Fezza, F., Bisogno, T., Bar, P.R., Veldink, G.A., Vliegenthart, J.F., Di Marzo, V., and Nicolay, K. (2001). Exogenous anandamide protects rat brain against acute neuronal injury in vivo. J. Neurosci. 21, 8765-8771.
14. Hwang, J., Adamson, C., Butler, D., Janero, D.R., Makriyannis, A., and Bahr, B.A. (2010). Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality. Life Sci. 86, 615-623.
15. Naidoo, V., Karanian, D.A., Vadivel, S.K., Locklear, J.R., Wood, J.T., Nasr, M., Quizon, P.M., Graves, E.E., Shukla, V., Makriyannis, A., and Bahr, B.A. (2012). Equipotent inhibition of fatty acid amide hydrolase and monoacylglycerol lipase-dual targets of the endocannabinoid system to protect against seizure pathology. Neurotherapeutics 9, 801-813.
16. Mechoulam, R., Panikashvili, D., and Shohami, E. (2002). Cannabinoids and brain injury: therapeutic implications. Trends Mol. Med. 8, 58-61.
17. Savinainen, J.R., Saario, S.M., and Laitinen, J.T. (2012). The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors. Acta Physiol. (Oxf) 204, 267-276.
18. Blankman, J.L., Simon, G.M., and Cravatt, B.F. (2007). A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2- arachidonoylglycerol. Chem. Biol. 14, 1347-1356.
19. Marrs, W.R., Blankman, J.L., Horne, E.A., Thomazeau, A., Lin, Y.H., Coy, J., Bodor, A.L., Muccioli, G.G., Hu, S.S., Woodruff, G., Fung, S., Lafourcade, M., Alexander, J.P., Long, J.Z., Li, W., Xu, C., Möller, T., Mackie, K., Manzoni, O.J., Cravatt, B.F., and Stella, N. (2010). The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nat. Neurosci. 13, 951-957.
20. Chanda, P.K., Gao, Y., Mark, L., Btesh, J., Strassle, B.W., Lu, P., Piesla, M.J., Zhang, M.Y., Bingham, B., Uveges, A., Kowal, D., Garbe, D., Kouranova, E.V., Ring, R.H., Bates, B., Pangalos, M.N., Kennedy, J.D., Whiteside, G.T., and Samad, T.A. (2010). Monoacylglycerol lipase activity is a critical modulator of the tone and integrity of the endocannabinoid system. Mol. Pharmacol. 78, 996-1003.
21. Schlosburg, J.E., Blankman, J.L., Long, J.Z., Nomura, D.K., Pan, B., Kinsey, S.G., Nguyen, P.T., Ramesh, D., Booker, L., Burston, J.J., Thomas, E.A., Selley, D.E., Sim-Selley, L.J., Liu, Q.S., Lichtman, A.H., and Cravatt, B.F. (2010). Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat. Neurosci. 13, 1113-1119.
22. Mangieri, R.A., and Piomelli, D. (2007). Enhancement of endocannabinoid signaling and the pharmacotherapy of depression. Pharmacol. Res. 56, 360-366.
23. Scotter, E.L., Abood, M.E. and Glass, M. (2010). The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br. J. Pharmacol. 160, 480-498.
24. Marrs, W.R., Horne, E.A., Ortega-Gutierrez, S., Cisneros, J.A., Xu, C., Lin, Y.H., Muccioli, G.G., Lopez-Rodriguez, M.L., and Stella, N. (2011). Dual inhibition of alpha/beta-hydrolase domain 6 and fatty acid amide hydrolase increases endocannabinoid levels in neurons. J. Biol. Chem. 286, 28723-28728.
25. Myer, D.J., Gurkoff, G.G., Lee, S.M., Hovda, D.A., and Sofroniew, M.V. (2006). Essential protective roles of reactive astrocytes in traumatic brain injury. Brain 129, 2761-2772.
26. Di Filippo, C., Rossi, F., Rossi, S., and D'Amico, M. (2004). Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMN. J. Leukoc. Biol. 75, 453-459.
27. Sell, S.L., Avila, M.A., Yu, G., Vergara, L., Prough, D.S., Grady, J.J., and DeWitt, D.S. (2008). Hypertonic resuscitation improves neuronal and behavioral outcomes after traumatic brain injury plus hemorrhage. Anesthesiology 108, 873-881.
28. Galante, M., Jani, H., Vanes, L., Daniel, H., Fisher, E.M., Tybulewicz, V.L., Bliss, T.V., and Morice, E. (2009). Impairments in motor coordination without major changes in cerebellar plasticity in the Tc1 mouse model of Down syndrome. Hum. Mol. Genet. 18, 1449-1463.
29. Bryan, K.J., Lee, H., Perry, G., Smith, M.A., and Casadesus, G. (2009). Transgenic mouse models of alzheimer's disease: behavioral testing and considerations. In: Methods of Behavior Analysis in Neuroscience. Buccafusco, J.J. (ed). CRC Press: Boca Raton (FL).
30. Chauhan, N.B., Gatto, R., and Chauhan, M.B. (2010). Neuroanatomical correlation of behavioral deficits in the CCI model of TBI. J. Neurosci. Methods 190, 1-9.
31. Yu, F., Zhang, Y., and Chuang, D.M. (2012). Lithium reduces BACE1 overexpression, beta amyloid accumulation, and spatial learning deficits in mice with traumatic brain injury. J. Neurotrauma 29, 2342-2351.
32. Tanaka, K., Yagi, T., Shimakoshi, R., Azuma, K., Nanba, T., Ogo, H., Tamura, A., and Asanuma, M. (2009). Effects of galantamine on LNAME-induced behavioral impairment in Y-maze task in mice. Neurosci. Lett. 462, 235-238.
33. Lloyd, E., Somera-Molina, K., Van Eldik, L.J., Watterson, D.M., and Wainwright, M.S. (2008). Suppression of acute proinflammatory cytokine and chemokine upregulation by post-injury administration of a novel small molecule improves long-term neurologic outcome in a mouse model of traumatic brain injury. J. Neuroinflammation 5, 28.
34. Canas, P.M., Porciuncula, L.O., Cunha, G.M., Silva, C.G., Machado, N.J., Oliveira, J.M., Oliveira, C.R., and Cunha, R.A. (2009). Adenosine A2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by beta-amyloid peptides via p38 mitogen-activated protein kinase pathway. J. Neurosci. 29, 14741-14751.
35. Dauge, V., Sebret, A., Beslot, F., Matsui, T., and Roques, B.P. (2001). Behavioral profile of CCK2 receptor-deficient mice. Neuropsychopharmacology 25, 690-698.
36. Tchantchou, F., Graves, M., Ortiz, D., Rogers, E., and Shea, T.B. (2004). Dietary supplementation with 3-deaza adenosine, N-acetyl cysteine, and S-adenosyl methionine provide neuroprotection against multiple consequences of vitamin deficiency and oxidative challenge: relevance to age-related neurodegeneration. Neuromolecular Med. 6, 93-103.
37. Dall'Igna, O.P., Fett, P., Gomes, M.W., Souza, D.O., Cunha, R.A., and Lara, D.R. (2007). Caffeine and adenosine A(2a) receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice. Exp. Neurol. 203, 241-245.
38. Hughes, R.N. (2004). The value of spontaneous alternation behavior (SAB) as a test of retention in pharmacological investigations of memory. Neurosci. Biobehav. Rev. 28, 497-505.
39. Dash, P.K., Orsi, S.A., Zhang, M., Grill, R.J., Pati, S., Zhao, J., and Moore, A.N. (2010). Valproate administered after traumatic brain injury provides neuroprotection and improves cognitive function in rats. PLoS One 5, e11383.
40. Schmued, L.C., and Hopkins, K.J. (2000). Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration. Brain Res. 874, 123-130.
41. Tchantchou, F., Xu, Y., Wu, Y., Christen, Y., and Luo, Y. (2007). EGb 761 enhances adult hippocampal neurogenesis and phosphorylation of CREB in transgenic mouse model of Alzheimer's disease. FASEB J. 21, 2400-2408.
42. Ay, I., Francis, J.W., and Brown, R.H., Jr. (2008). VEGF increases blood-brain barrier permeability to Evans blue dye and tetanus toxin fragment C but not adeno-associated virus in ALS mice. Brain Res. 1234, 198-205.
43. Yu, F., Wang, Z., Tchantchou, F., Chiu, C.T., Zhang, Y., and Chuang, D.M. (2012). Lithium ameliorates neurodegeneration, suppresses neuroinflammation, and improves behavioral performance in a mouse model of traumatic brain injury. J. Neurotrauma 29, 362-374.
44. Hall, E.D., Bryant, Y.D., Cho, W., and Sullivan, P.G. (2008). Evolution of post-traumatic neurodegeneration after controlled cortical impact traumatic brain injury in mice and rats as assessed by the de Olmos silver and fluorojade staining methods. J. Neurotrauma 25, 235-247.
45. Frank, P.G., and Lisanti, M.P. (2008). ICAM-1: role in inflammation and in the regulation of vascular permeability. Am. J. Physiol. Heart Circ. Physiol. 295, H926-H927.
46. Di Lorenzo, A., Manes, T.D., Davalos, A., Wright, P.L., and Sessa, W.C. (2011). Endothelial reticulon-4B (Nogo-B) regulates ICAM-1-mediated leukocyte transmigration and acute inflammation. Blood 117, 2284-2295.
47. Liu, Y., Shaw, S.K., Ma, S., Yang, L., Luscinskas, F.W., and Parkos, C.A. (2004). Regulation of leukocyte transmigration: cell surface interactions and signaling events. J. Immunol. 172, 7-13.
48. Schneider, C., Schuetz, G., and Zollner, T.M. (2009). Acute neuroinflammation in Lewis rats-a model for acute multiple sclerosis relapses. J. Neuroimmunol. 213, 84-90.
49. Soetikno, V., Sari, F.R., Veeraveedu, P.T., Thandavarayan, R.A., Harima, M., Sukumaran, V., Lakshmanan, A.P., Suzuki, K., Kawachi, H., and Watanabe, K. (2011). Curcumin ameliorates macrophage infiltration by inhibiting NF-kappaB activation and proinflammatory cytokines in streptozotocin induced-diabetic nephropathy. Nutr. Metab. (Lond) 8, 35.
50. Kan, W.H., Hsu, J.T., Schwacha, M.G., Choudhry, M.A., Raju, R., Bland, K.I., and Chaudry, I.H. (2008). Selective inhibition of iNOS attenuates trauma-hemorrhage/resuscitation-induced hepatic injury. J. Appl. Physiol. 105, 1076-1082.
51. Martin-Moreno, A.M., Brera, B., Spuch, C., Carro, E., Garcia-Garcia, L., Delgado, M., Pozo, M.A., Innamorato, N.G., Cuadrado, A., and de Ceballos, M.L. (2012). Prolonged oral cannabinoid administration prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in Tg APP 2576 mice. J. Neuroinflammation 9, 8.
52. Elliott, M.B., Jallo, J.J., and Tuma, R.F. (2008). An investigation of cerebral edema and injury volume assessments for controlled cortical impact injury. J. Neurosci. Methods 168, 320-324.
53. Taylor, A.N., Rahman, S.U., Sanders, N.C., Tio, D.L., Prolo, P., and Sutton, R.L. (2008). Injury severity differentially affects short-and long-term neuroendocrine outcomes of traumatic brain injury. J. Neurotrauma 25, 311-323.
54. Hall, E.D., Sullivan, P.G., Gibson, T.R., Pavel, K.M., Thompson, B.M., and Scheff, S.W. (2005). Spatial and temporal characteristics of neurodegeneration after controlled cortical impact in mice: more than a focal brain injury. J. Neurotrauma 22, 252-265.
55. Iravani, M.M., Kashefi, K., Mander, P., Rose, S., and Jenner, P. (2002). Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. Neuroscience 110, 49-58.
56. Arimoto, T., and Bing, G. (2003). Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration. Neurobiol. Dis. 12, 35-45.
57. Loane, D.J., and Byrnes, K.R. (2010). Role of microglia in neurotrauma. Neurotherapeutics 7, 366-377.
58. Rojo, A.I., Innamorato, N.G., Martin-Moreno, A.M., De Ceballos, M.L., Yamamoto, M., and Cuadrado, A. (2010). Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease. Glia 58, 588-598.
59. Gao, X., Deng-Bryant, Y., Cho, W., Carrico, K.M., Hall, E.D., and Chen, J. (2008). Selective death of newborn neurons in hippocampal dentate gyrus following moderate experimental traumatic brain injury. J. Neurosci. Res. 86, 2258-2270.
60. Hilton, G.D., Stoica, B.A., Byrnes, K.R., and Faden, A.I. (2008). Roscovitine reduces neuronal loss, glial activation, and neurologic deficits after brain trauma. J. Cereb. Blood Flow Metab. 28, 1845-1859.
61. Straiker, A., Hu, S.S., Long, J.Z., Arnold, A., Wager-Miller, J., Cravatt, B.F., and Mackie, K. (2009). Monoacylglycerol lipase limits the duration of endocannabinoid-mediated depolarization-induced suppression of excitation in autaptic hippocampal neurons. Mol. Pharmacol. 76, 1220-1227.
62. Lenzlinger, P.M., Morganti-Kossmann, M.C., Laurer, H.L., and Mc-Intosh, T.K. (2001). The duality of the inflammatory response to traumatic brain injury. Mol. Neurobiol. 24, 169-181.
63. Li, B., Mahmood, A., Lu, D., Wu, H., Xiong, Y., Qu, C., and Chopp, M. (2009). Simvastatin attenuates microglial cells and astrocyte activation and decreases interleukin-1beta level after traumatic brain injury. Neurosurgery 65, 179-186.
64. Ahmad, M., Rose, M.E., Vagni, V., Griffith, R.P., Dixon, C.E., Kochanek, P.M., Hickey, R.W., and Graham, S.H. (2008). Genetic disruption of cyclooxygenase-2 does not improve histological or behavioral outcome after traumatic brain injury in mice. J. Neurosci. Res. 86, 3605-3612.
65. Clark, R.S., Kochanek, P.M., Schwarz, M.A., Schiding, J.K., Turner, D.S., Chen, M., Carlos, T.M., and Watkins, S.C. (1996). Inducible nitric oxide synthase expression in cerebrovascular smooth muscle and neutrophils after traumatic brain injury in immature rats. Pediatr. Res. 39, 784-790.
66. Khan, M., Im, Y.B., Shunmugavel, A., Gilg, A.G., Dhindsa, R.K., Singh, A.K., and Singh, I. (2009). Administration of Snitrosoglutathione after traumatic brain injury protects the neurovascular unit and reduces secondary injury in a rat model of controlled cortical impact. J. Neuroinflammation 6, 32.
67. Kunz, A., Park, L., Abe, T., Gallo, E.F., Anrather, J., Zhou, P., and Iadecola, C. (2007). Neurovascular protection by ischemic tolerance: role of nitric oxide and reactive oxygen species. J. Neurosci. 27, 7083-7093.
68. Zhang, J., and Chen, C. (2008). Endocannabinoid 2-arachidonoylglycerol protects neurons by limiting COX-2 elevation. J. Biol. Chem. 283, 22601-22611.
69. Du, H., Chen, X., Zhang, J., and Chen, C. (2011). Inhibition of COX-2 expression by endocannabinoid 2-arachidonoylglycerol is mediated via PPAR-gamma. Br. J. Pharmacol. 163, 1533-1549.
70. Thau-Zuchman, O., Shohami, E., Alexandrovich, A.G., Trembovler, V., and Leker, R.R. (2012). The anti-inflammatory drug carprofen improves long-term outcome and induces gliogenesis after traumatic brain injury. J. Neurotrauma 29, 375-384.
71. Kuo, H.S., Tsai, M.J., Huang, M.C., Chiu, C.W., Tsai, C.Y., Lee, M.J., Huang, W.C., Lin, Y.L., Kuo, W.C., and Cheng, H. (2011). Acid fibroblast growth factor and peripheral nerve grafts regulate Th2 cytokine expression, macrophage activation, polyamine synthesis, and neurotrophin expression in transected rat spinal cords. J. Neurosci. 31, 4137-4147.
72. Lee, S., Huen, S., Nishio, H., Nishio, S., Lee, H.K., Choi, B.S., Ruhrberg, C., and Cantley, L.G. (2011). Distinct macrophage phenotypes contribute to kidney injury and repair. J. Am. Soc. Nephrol. 22, 317-326.
73. Lourbopoulos, A., Grigoriadis, N., Lagoudaki, R., Touloumi, O., Polyzoidou, E., Mavromatis, I., Tascos, N., Breuer, A., Ovadia, H., Karussis, D., Shohami, E., Mechoulam, R., and Simeonidou, C. (2011). Administration of 2-arachidonoylglycerol ameliorates both acute and chronic experimental autoimmune encephalomyelitis. Brain Res. 1390, 126-141.
74. Nomura, D.K., Morrison, B.E., Blankman, J.L., Long, J.Z., Kinsey, S.G., Marcondes, M.C., Ward, A.M., Hahn, Y.K., Lichtman, A.H., Conti, B., and Cravatt, B.F. (2011). Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 334, 809-813.
75. Oz, M. (2006). Receptor-independent actions of cannabinoids on cell membranes: focus on endocannabinoids. Pharmacol. Ther. 111, 114-144.
76. Izzo, A.A., Fezza, F., Capasso, R., Bisogno, T., Pinto, L., Iuvone, T., Esposito, G., Mascolo, N., Di Marzo, V., and Capasso, F. (2001). Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br. J. Pharmacol. 134, 563-570.
77. Jeong, W.I., Osei-Hyiaman, D., Park, O., Liu, J., Batkai, S., Mukhopadhyay, P., Horiguchi, N., Harvey-White, J., Marsicano, G., Lutz, B., Gao, B., and Kunos, G. (2008). Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metab. 7, 227-235.
78. Julien, B., Grenard, P., Teixeira-Clerc, F., Van Nhieu, J.T., Li, L., Karsak, M., Zimmer, A., Mallat, A., and Lotersztajn, S. (2005). Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 128, 742-755.
79. Teixeira-Clerc, F., Julien, B., Grenard, P., Tran Van Nhieu, J., Deveaux, V., Li, L., Serriere-Lanneau, V., Ledent, C., Mallat, A., and Lotersztajn, S. (2006). CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat. Med. 12, 671-676.
80. van der Poorten, D., Shahidi, M., Tay, E., Sesha, J., Tran, K., McLeod, D., Milliken, J.S., Ho, V., Hebbard, L.W., Douglas, M.W., and George, J. (2010). Hepatitis C virus induces the cannabinoid receptor 1. PLoS One 5.
81. Galve-Roperh, I., Aguado, T., Palazuelos, J., and Guzman, M. (2008). Mechanisms of control of neuron survival by the endocannabinoid system. Curr. Pharm. Des. 14, 2279-2288.
82. Diaz-Laviada, I., and Ruiz-Llorente, L. (2005). Signal transduction activated by cannabinoid receptors. Mini. Rev. Med. Chem. 5, 619-630.
83. Molina-Holgado, F., Rubio-Araiz, A., Garcia-Ovejero, D., Williams, R.J., Moore, J.D., Arevalo-Martin, A., Gomez-Torres, O, and Molina-Holgado, E. (2007). CB2 cannabinoid receptors promote mouse neural stem cell proliferation. Eur. J. Neurosci. 25, 629-634.
84. Horne, E.A., Marrs, W., Kalume, F., Blankman, J., Li, W., Coy, J., Swinney, K., Cherry, A., Fung, S., Cravatt, B., Oakley, J.C. and Stella, N. (2011). CB1 regulates epileptic activity in a mouse model of earlyonset Huntington's disease. Presented at the Society for Neuroscience Annual Meeting, pp p.668.606/Q662.